A Randomized Controlled Trial of the Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Compare the frequency of diarrheal events grade 2 or greater by CTCAE version 4.0 in patients receiving abdominal or pelvic chemoradiation with a fluoropyrimidine who are treated with the probiotic LGG to the frequency of these events in patients receiving abdominal or pelvic chemoradiation with a fluoropyrimidine who receive placebo
Matthew Ciorba, M.D.
Washington University School of Medicine
United States: Institutional Review Board
|Washington University School of Medicine||Saint Louis, Missouri 63110|